Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Medical device litigation and COVID-19: What you need to know

June 30, 2020 By Chris Newmarker

The COVID-19 pandemic is creating a new set of medical device litigation challenges — but also a chance for an industry reset. One of Greenberg Traurig’s top medtech litigation lawyers shares her insights.

medical device litigation medtech COVID-19 coronavirus

[Gavel image from Unsplash. Coronavirus image from WHO]

Sara Thompson doesn’t take any guff when she tells people that she defends medical device and pharmaceutical companies from lawsuits.

“I say, ‘I sleep great at night because the companies I represent make things that can save and sustain life,’” said Thompson, who is vice chair of the Pharmaceutical, Medical Device & Health Care Litigation Practice at Greenberg Traurig.

Thompson thinks the case in defense of medtech is even stronger now that Americans and people around the world desperately need medical devices, drugs and vaccines to overcome the COVID-19 pandemic.

“Both drug and device companies want to help. A lot of our clients are developing ventilators, or they’re making their ventilators open-source. They’re contributing parts, and they’re contributing manufacturing space,” Thompson recently told Medical Design & Outsourcing.

Thompson summed it up: “I think it’s changing public perceptions in a way that once we get to trials will also be interesting. There’s going to be a lot of reverberations of this for a long time, I would say.”

Most commentators agree that COVID-19 is creating a new normal, and medtech litigation is no exception. Improved public perception is but one of a number of changes taking place. Here are five other ways Thompson sees the space evolving:

1. Companies are reevaluating litigation

For now, many medical device companies have taken a sales hit as health providers scale back on elective procedures and people even hold off on potentially necessary procedures amid the pandemic. CEOs of major companies have said in recent earnings calls that they expect revenue to recover later this year, but Thompson also sees them reevaluating the situation when it comes to lawsuits.

“We’re seeing our clients say, ‘Is this something we should reconsider in our strategy? Do we want to just resolve this case now? Should we reconsider a previous settlement?” Thompson said.

It’s all about adapting a litigation strategy to meet the medtech industry’s changing realities, according to Thompson.

“Some companies may be thinking, ‘We may not have the budget to go to trial anytime soon.’ So those worries could impact our assumptions and plan.”

2. More leeway to defer cases

Tighter budgets make medical device company officials less eager to go to trial right now, but Thompson also sees the pandemic giving them stronger arguments to get cases deferred down the road.

Judges care about the context when a lawyer is making a case. It may be necessary, for example, to reschedule a corporate employee’s deposition for a later date because the employee is focused on an essential program related to COVID-19.

“That really moves the needle for judges in a way that just saying that discovery would cause a business disruption often does not,” Thompson said.

3. Lawsuit immunity isn’t a given amid pandemic

The FDA has granted a host of emergency use authorizations during the pandemic to boost the availability of needed medical devices, virus and antibody tests, pharmaceuticals and more. Thompson suspects courts will be fleshing out for some time how much lawsuit immunity the FDA granted with its EUAs.

“Whenever there’s an intention that an immunity or a preemption (will) be broad, you always have very creative plaintiffs’ attorneys who try to find the cracks or the contours of that,” Thompson said.

There’s an exception for willful or wanton conduct, for example. “How’s that going to work? What are examples going to be?”

A company, for example, may have had a product on the market for another use, and then it received an EUA for a COVID-specific use. “Let’s say plaintiffs were raising design issues prior to all of that happening. Does the immunity apply to those claims? If the EUA is later revoked, does the immunity still apply? Those are real open questions for us to figure out,” Thompson said.

“There are a lot of really interesting and novel legal issues that we’re going to be litigating for the next few years.”

4. Less litigation tourism

It should also be easier for medical device and pharmaceutical companies to defend themselves from lawsuits. That’s because “litigation tourism” appears to be on its way out after the U.S. Supreme Court’s ruling in Bristol-Myers Squibb v. Superior Court of California, San Francisco County.  The 2017 decision makes it much harder for lawyers to shop for plaintiff-friendly courts in which to file their lawsuits, Thompson said.

“It’s not impossible if you have a plaintiff who lives there or has experienced an injury there, or if you have a defendant who’s either incorporated in or has their principal place of business there. But you’re not going to have a company located in Minnesota, being named in a case in a West Virginia state court when there’s no connection to the venue.”

5. Sales rep training is more important than ever

More than a decade has gone by since the Supreme Court’s Riegel v. Medtronic decision, which found that federal medical device regulation laws provide lawsuit protections for devices with FDA premarket approval.

Since then, plaintiff lawyers have focused less on a device’s design, warnings or performance and more on a company’s conduct, especially when it comes to sales representatives, according to Thompson. “Plaintiffs may allege the sales representative trained a doctor, and if so, did they train the doctor how to use a device in a way that led to or allegedly led to the injury? Or did the doctor have a sales representative directly interacting with a patient in some impermissible way?”

Courts are scrutinizing adverse event reporting, too.

As medical device companies rethink how they market products to health providers during the pandemic and beyond, it’s more important than ever that they make sure their sales reps know what conduct is appropriate and err on the side of caution when deciding whether to report problems, Thompson said.

Related Articles Read More >

Picture of SCOTUS Supreme Court building in Washington
How medical device companies are responding to abortion bans
Philips
Philips updates on testing results for recalled ventilators
A portrait of Proximie CEO Nadine Hachach-Haram
They said it at DeviceTalks Boston
Marketing image for Diversity by Doing HealthTech DxD
Summer health technology program brings diverse group of interns to Silicon Valley

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech